Marshall Wace North America’s Moderna MRNA Stock Holding History

Marshall Wace North America’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$2.21M	Sell	5,750 -32,102	-85%	-$11.8M	0.01%	703
2021 Q2	$8.89M	Sell	37,852 -27,535	-42%	-$4.92M	0.04%	395
2021 Q1	$8.56M	Sell	65,387 -293,307	-82%	-$42.5M	0.04%	426
2020 Q4	$37.5M	Buy	+358,694	New	+$36.3M	0.17%	151
2020 Q3	–	Sell	-122,713	Closed	-$7.88M	–	1380
2020 Q2	$7.88M	Buy	+122,713	New	+$6.72M	0.05%	301
2019 Q3	–	Sell	-190,944	Closed	-$2.8M	–	1454
2019 Q2	$2.8M	Buy	+190,944	New	+$4.1M	0.02%	483

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Marshall Wace North America's MRNA Position: Q3 2021 in Review

Marshall Wace North America reduced its Moderna (MRNA) stake by 85% in Q3 2021, selling an estimated $11.8M and leaving 5,750 shares worth $2.21M. The position accounts for 0.01% of the portfolio, ranked #703.

Marshall Wace North America first reported a position in MRNA in Q2 2019 and has held it in 6 quarters since. The position peaked at $37.5M in Q4 2020. 1,142 funds tracked by Wall St. Rank hold MRNA as of Q3 2021.

Marshall Wace North America held 5,750 shares of Moderna worth $2.21M as of Q3 2021.
Marshall Wace North America sold 32,102 Moderna shares in Q3 2021, an estimated $11.8M.
Moderna made up 0.01% of Marshall Wace North America's portfolio in Q3 2021, its #703 holding.
Marshall Wace North America first reported a position in Moderna in Q2 2019 and has held it in 6 quarters since.
Marshall Wace North America's Moderna position peaked at $37.5M in Q4 2020.
1,142 funds tracked by Wall St. Rank held Moderna as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.